News and outlook
Phase 2a results for the treatment of PSP have confirmed the commitment of the progranulin target, and initial signs of clinical efficacy have been observed and presented to European and American key opinion leaders. They were also presented at several conferences:
– CTAD (Clinical Trials for Alzheimer Disease) in San Francisco (Nov 2022);
– ADPD (Alzheimer Disease Parkinson Disease) in Gothenburg (March 2023) ;
– EuroTau (April 2023);
– Neuro 2023 International Research Symposium (October)
The health authorities and ethics committee have given the go-ahead for the Phase 2a study to be extended to 2023. Patients in this study will be treated for 6 months with the highest dose. This study will make it possible to treat patients for longer and provide additional results. The first set-up took place on May 2, 2023 at the Lille University Hospital.
The company continues its collaboration with the Michael J. Fox Foundation, extending Alzprotect’s research efforts to develop AZP2006 for Parkinson’s disease. In vitro study objectives have been met, confirming the interest of AZP2006’s mechanism of action.